82 research outputs found
Older patients with chronic myeloid leukemia (≥65 years) profit more from higher imatinib doses than younger patients: a subanalysis of the randomized CML-Study IV
Distinct characteristics of e13a2 versus e14a2 BCR-ABL1 driven chronic myeloid leukemia under first-line therapy with imatinib
Nilotinib first-line therapy in patients with Philadelphia chromosome-negative/BCR-ABL-positive chronic myeloid leukemia in chronic phase: ENEST1st sub-analysis
The development of dasatinib as a treatment for chronic myeloid leukemia (CML): from initial studies to application in newly diagnosed patients
Modelle fuer die laendliche Energieversorgung mit Photovoltaik in Entwicklungslaendern: Klassifizierung bestehender Verbreitungsstrategien
Achieving early molecular response in chronic myeloid leukemia in chronic phase to reduce the risk of progression: clinical relevance of the 3‐ and 6‐month time points
The predictive impact of MDR1 expression and pre-tumor burden on molecular, cytogenetic and clinical outcome of CML patients on nilotinib therapy after imatinib failure
Outcome of CML patients with ABL tyrosine kinase mutations after hematological resistance to imatinib
- …